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Selective antagonism of the AT1 receptor inhibits angiotensin II
stimulated DNA and protein synthesis in primary cultures of human
proximal tubular cells. The hypertrophy of renal proximal tubular cells
occurs as an adaptive response to a variety of stimuli and may be involved
with the progression of renal disease. Angiotensin II acting alone or in
combination with other growth factors has been implicated in this process.
The aims of this study were to identify the role of both angiotensin II and
the angiotensin receptor subtypes in DNA synthesis and protein synthesis
in human renal proximal tubular cells. Primary cultures of human renal
proximal tubular cells were incubated with angiotensin II (10° M,
1O M, 10 M) for 24 to 120 hours either alone or in combination with
losartan, PD123319 or 8-bromo-cAMP. Incubation of human proximal
tubular cells with angiotensin 11(10—0 M, i0 M) induced a significant
early increase in [3Hthymidine uptake by 19% and 56% (P < 0.01),
respectively, and a later increase in total protein content by 30% (P <
0.01). The effect of angiotensin II upon DNA and protein synthesis was
inhibited by 8-bromo-cAMP and losartan but not by PD123319, indicating
that the responses are mediated via the AT1 receptor and dependent upon
the inhibition of adenylate cyclase.
The hypertrophy of the renal tubulointerstitium in renal dis-
eases such as glomerulonephritis indicates a poor prognosis for
recovery, often resulting in interstitial fibrosis and end-stage renal
failure [1, 2]. While it is clear that hypertrophy of glomerular cells
represents a poor prognostic indicator in a variety of renal disease
states [3], less is known about the role of compensatory hypertro-
phy of the proximal tubule cell (PTC). It has been suggested,
however, that such PTC hypertrophy may also be a maladaptive
process and play a pivotal role in renal disease progression [2].
Although the cellular mechanisms involved in the pathological
alteration of tubular growth have not been fully elucidated it is
clear that vasoactive peptides such as angiotensin II (Ang II) are
probably involved [4].
While the homeostatic role of Ang II is now well established [5],
less is known about its potent growth regulatory functions [6—9].
Ang II has been reported to have growth factor-like actions in a
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number of renal cells [10—13] and to stimulate the transcription
and synthesis of type IV collagen, an integral constituent of the
basement membrane [14] and a necessary prelude to Ang II
induced hypertrophy [10].
Studies in vivo serve to reinforce these findings. Ang II infusion
into rats has been reported to produce tubular hypertrophy, an
increase in type IV collagen deposition [15] and an increase in the
transcription of the growth related proto-oncogenes c-fos and
Egr-1 [16]. The place of angiotensin converting enzyme (ACE)
inhibitors such as captopril in the treatment and amelioration of
human diabetic nephropathy is now well established [17], but
ACE inhibitors and selective Ang II antagonists have also been
reported to ameliorate or shorten the course of renal disease in
animal models of interstitial fibrosis and glomerulosclerosis [18—
20]. It has been suggested that the growth-promoting effects of
Ang II may result from autocrine or paracrine activation of
cytokines such as platelet-derived growth factor (PDGF) or
transforming growth factor-beta (TGF-B) [21], however, the exact
mechanisms involved in altered tubular growth are unclear.
The aim of this study was to determine whether Ang II could
stimulate cellular DNA and protein synthesis in primary cultures
of human proximal tubular (HPT) cells, and, if so, which angio-
tensin receptor subtype was involved.
METHODS
Isolation and culture of HPT cells
HPT cells were prepared as previously described [22], from the
unaffected pole of kidneys removed at nephrectomy. Briefly, 10 to
15 g of macroscopically normal cortex was chopped and washed in
Hank's buffer after which the tissue was digested for one hour at
37°C in modified Hank's buffer containing 0.32 U/mI collagenase
A (Boehringer Mannheim, Sussex, UK). The resultant suspension
was then filtered through a 75 fim filter, pelleted and washed in
Hank's buffer. The cell mixture was then resuspended in Percoll
buffer solution (Percoll; Sigma Chemical Co., Dorset, UK) with a
starting density of 1.044 g/ml and centrifuged at 13,000 r.p.m.
(20,000 g) at 4°C for 30 minutes. After centrifugation three bands
were obtained at densities 1.04, 1.06 and 1.065 g/ml. Cells from
the 1.06 g/ml band were removed, pelleted and resuspended in
ice-cold Dulbecco's Modified Eagle's Medium/Ham's Fl 2 nutri-
tional supplement (DMEM/Ham's F12 1:1 vol/vol; Gibco BRL,
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Scotland, UK). An aliquot of cell suspension was removed for
determination of cell number and viability using the Trypan blue
exclusion method.
Cell culture
HPT cells were seeded onto 3.5 cm plastic plates (Costar,
Buckinghamshire, UK) at a seeding density of 1 X 106 cells/plate
(1 x io cells/cm2) and allowed to attach overnight in serum-
supplemented medium. The cells were cultured in DMEM/Ham's
F12 containing D-glucose (17.5 mmol/liter), sodium bicarbonate
(12.5 mmol/liter) supplemented with 10% fetal calf serum (FCS,
Gibeo), 50 lU/mI penicillin (Gibco) and 50 ig/ml streptomycin
(Gibco). Cultures were maintained in an incubator at 37°C within
a humidified atmosphere of 95% air/5% CO2 with medium
changed every 48 hours.
Incubation with Ang II, losartan, PD123319 and
8-bromo-cAMP
After a further 48 hour period, medium was replaced by
DMEM/Ham's Fl2 containing 10% FCS in the presence or
absence of Ang II (10b0, 108 or 10-6 Sigma).
Because consistently significant effects upon DNA and protein
synthesis, compared to baseline were observed following incuba-
tion with Ang II 10 M and at days 3 to 5 and 7 to 10
post-seeding, respectively, this concentration of Ang II and the
time points at days 5, 7, 10 were chosen for all further experiments
using the AT1 and AT2 antagonists.
HPT cells were incubated with losartan (106 M; DuPont,
Detroit, MI, USA), or PD123319 (106 Parke-Davis, Detroit,
Ml, USA), or 8-bromo-cAMP (106 M, Sigma) either in the
presence or absence of Ang II (108 M). Medium was changed
every two days.
Measurement of cellular DNA synthesis
Cellular DNA synthesis was estimated using [3H]thymidine (26
Ci/mmol; Amersham International plc, Little Chalfont, Bucks,
UK) incorporation into cell DNA. Cultures were pulsed for one
hour with I Ci/ml [3Hjthymidine at 37°C in a humidified 95%
air/5% CO2 atmosphere after which they were washed twice with
ice-cold phosphate buffered saline (PBS). The cells were then left
for 30 minutes in 1 ml ice-cold perchloric acid (0.2 M), after which
they were again washed twice with PBS before being scraped into
1 ml NaOH (0.3 M). Radioactivity in samples was determined
using liquid scintillation counting and measured on a Packard
Tri-Carb Liquid Scintillation Analyser (Canberra Packard, Pang-
bourne, Berkshire, UK) with external standard quench correction.
Measurement of RNA synthesis
Total RNA synthesis was estimated using [3H]uridine (26
Ci/mmol; Amersham International plc, Little Chalfont, Bucks,
UK) incorporation into cell RNA. [31-l]uridine was added to
growth media to produce a final concentration of I Ci/ml and the
cultures were incubated for 24 hours at 37°C in a humidified 95%
air/5% CO2 atmosphere. On completion of incubation, the cul-
tures were washed twice with ice-cold PBS and then scraped into
1 ml NaOH (0.3 M). The radioactivity content of samples was
measured as described above.
Measurement of de novo protein synthesis
Incorporation of [3H]leucine (158 Ci/mmol; Amersham Inter-
national plc) was used as a sensitive measure of de novo protein
synthesis. After addition of [3H]leucine to the growth media to
produce a final concentration of 5 Ci/ml, the cultures were
incubated for 24 hours at 37°C in a humidified 95% air/5% CO2
atmosphere. Cultures were then washed twice with ice-cold PBS
after which 1 ml ice-cold trichioroacetic acid solution (10% w/v)
was added. Following 10 minutes on ice, this step was repeated
twice. After another two washes in PBS, the cell residue left on the
plate was solubilized in 1 ml NaOH (0.3 M). The radioactive
content of samples was determined as described above.
Measurement of total protein content
The total protein content of samples was measured using a
modification of the Lowry assay [23] using bovine serum albumin
to produce a standard curve.
Presentation of data and statistical analysis
Results obtained from the [3H]thymidine incorporation were
expressed as dpm/mg protein/hour, [3H]uridine and [3H]leucine
assays results were expressed as dpm/mg protein/24 hours. The
total protein content of cultures was expressed as mg protein/
plate. The data are presented as mean so. Statistical signifi-
cance was determined using a one way ANOVA. A P value of less
than 0.05 was considered to indicate significance.
RESULTS
HPT cell characterization
Primary cultures of HPT cells grew to form confluent mono-
layers over seven days and exhibited the cobblestone morphology
characteristic of epithelial cells. The cultures maintained their
epithelial appearance throughout the duration of the experiments
with no significant evidence of fibroblast contamination or over-
growth. We have previously reported that HPT cultures prepared
and grown in this manner maintain phlorizin-inhibitable Nat-
dependent D-glucose transport [24], anion and cation transport
mechanisms and a significant cAMP response to parathyroid
hormone (106 M) with no similar response to vasopressin
(10—6 M) or calcitonin (106 M). Prior to use HPT cells were also
characterized according to their immunohistochemical and renal
enzyme histochemical staining as previously described [25].
Effect of angiotensin II on HPT cell cultures
Incubation of HPT cell cultures with Ang 1110—10 and 108 M
produced a significant increase in [3Hjthymidine uptake of 19%
and 42%, respectively (621 39 X iO to 736 40 >( io
[10b0 M], 882 72>< i03 [108 M], dpm/mg protein/hour, N =4,
P < 0.01), compared with control (Fig. 1A). The maximal effect
was observed at day 5 of incubation.
After seven days in culture, the cells attained confluence. From
this time point onwards, Ang II stimulated a significant increase in
total cell protein content (Fig. 1B), RNA synthesis measured as
[3H]uridine uptake (Fig. 1C) and protein synthesis measured as
[3H]leucine uptake (Fig. 1D). After 10 days incubation with Mg
II (1O and 10_6 M) total protein content increased by 20% and
22%, respectively [0.860 0.06 to 1.035 0.02 (108 M) and
1.050 0.03 (106 M) mg protein/plate, N = 4, P < 0.01),
compared with control. Because the maximal effect on DNA and
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Fig. 1. A. I3Hlthymidine uptake by cultures of HPT cells after 5, 7 and 10 days exposure to Ang II (10'°, io— and l0_6 M) (N = 4). (B) The total
protein content of HPT cells after 7 and 10 days expose to Ang II (El 10, and III l0' M; N = 4; P < 0.01 vs. U control). (C) The effect of
Ang 11(10—8 M) upon [3Hluridine incorporation into HPT cells following 7 and 10 days incubation (N = 4); symbol (U) is control. (D) The effect of
Ang II (F 10—8 M) upon [3H]leucine incorporation into HPT cells following 7 and 10 days incubation (N 4; P < 0.01 vs. U control).
protein synthesis was observed for cells incubated with Ang II
10 M all further experiments were carried out with this concen-
tration of Ang II. Incubation with Ang II 10 M also produced a
significant increase in [3Hjuridine uptake by 45% (1872 96 X
to 2712 96 >< iO (10_8 M) dpm/mg protein/24 hr, N = 4,
P < 0.011 and [3H]leucine uptake by 26% (737 17 X IO to
931 38 X 10 [10 M] dpm/mg protein/24 hr, N = 4, P < 0.01)
at day 10.
Effect of losartan and PD123319 upon angiotensin
11-stimulated HPT cell cultures
By day 5, incubation with losartan produced a significant 29%
inhibition of Aug 11-stimulated DNA synthesis returning levels to
control values [882 72 X iO (Ang 1110 M) to 626 93 X iO
dpm/mg protein/hr (Ang 11 10 M + losartan i0' M, N = 4, 1' <
0.01; Fig. 2A]. At day 10 losartan also produced a significant 20%
inhibition of Ang 11-stimulated total protein content (1.04 0.02
to 0.83 0.09 mg protein/plate, N = 4, P < 0.01; Fig. 2B), 33%
reduction in [3Hjuridine uptake (2712 96 >< i0 to 1824 72 1<
io dpm/mg protein/24 hr, N = 4, P < 0.01; Fig. 2C) and a 23%
reduction in [3H}leucine uptake (931 38 x IO to 721 5 >< iO
dpm/mg protein/24 hr, N = 4, P < 0.01; Fig. 2D). Incubation with
losartan completely blocked the effects of Ang II upon DNA and
protein synthesis. Incubation with PD123319 had no effect on Ang
Il-stimulated DNA, RNA or protein synthesis.
Effect of 8-bromo-cAMP upon angiotensin Il-stimulated DNA
and protein synthesis
Incubation with 8-bromo-cAMP (10 M) produced similar
effects to those observed with losartan returning all values
following incubation with Ang 11 to baseline. 8-Bromo-cAMP
produced a significant 29% inhibition of Aug 11-stimulated
[3Hjthymidine uptake (882 72 >< iO to 625 50 x iO dpm/mg
protein/hr, N 4, P < 0.01; Fig. 3A) of total protein content by
26% (1.04 0.02 to 0.78 0.06 mg protein/plate, N = 4, P <
0.01; Fig. 3B), ol' [3H]uridine uptake by 35% (2712 96 X i0 to
1776 48 )< iO dpm/rng protein/24 hr, N = 4, P < 0.01; Fig. 3C)
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Fig. 2. A. Effect of losartan and PD123319 (both 106M) on Ang Il-induced thymidine incorporation into HPT cells following 5,7 and 10 days exposure
to Ang 11(10—8 M; N = 4). (B) The effect of losartan and PD123319 (both 10—6 M) on total protein content of HPT cells following 7 and 10 days exposure
to Ang 11(10—8 M; N = 4; P < 0.01 vs. control; +P < 0.01 vs. 10 M Ang II). Symbols are: (U) control; (El) 10—6 M lostartan; (lJ) 106 M PD123319;
() 10—8 M Ang II; () 10—8 M Ang II + 10 M lostartan; () 10—8 M Ang II + 10—6 M PD123319. (C) The effect of losartan and PD123319 (both 106
M) on Ang II stimulated [3H]uridine incorporation into HPT cells following 7 and 10 days incubation with Ang 11(10—8 M; N 4). (D) The effect of
losartan and PD123319 (both 10-6 M) on Ang II stimulated [3H]leucine incorporation into HPT cells following 7 and 10 days incubation with Ang II
(10—8 M; N = 4; < 0.01 vs. control; +P < 0.01 vs. i0 M Ang II). Symbols are: (U) control; () 10—8 M Ang II; (l) iO M Ang II + 10—6 M lostartan;() 10 M Ang II + 10_6 M PD123319.
and [3H]leucine by 28% (931 38 X i0 to 670 5 )< iO
dpm/mg protein/24 hr, N = 4, P < 0.01; Fig. 3D).
DISCUSSION
Proliferation and compensatory hypertrophy of PT cells follow-
ing recovery from acute and chronic renal damage are adaptive
responses essential for the re-establishment of the tubule and
maintenance of glomerular filtration [26]. It has, however, been
suggested that hypertrophy of the PT cell may in part contribute
to the progression of chronic renal disease and end-stage renal
failure [9]. In vivo and in vitro studies suggest that Ang II may play
an important role in these changes. In vitro, Ang II has been
reported to stimulate cell hypertrophy in a variety of renal cell
lines including the murine SV4O virus-transformed PT cell line
[10], porcine LLC-PK1 cell line [11] and murine mesangial cells
[121. In vivo, the administration of ACE inhibitors and Ang II
receptor antagonists to animal models of glomerulosclerosis and
interstitial fibrosis has been reported to ameliorate and fore-
shorten the disease process [18—20]. Although prospective studies
have confirmed the place of ACE inhibitors in the treatment and
amelioration of diabetic nephropathy, little is known about the
mechanism of action of Ang II or selective Ang II antagonists on
the human kidney. Furthermore, all of the in vivo and in vitro
studies have been performed in animal models or non-human or
virally transformed immortalized cell lines, which differ consider-
ably in biochemical characteristics from the human PT cell.
The aim of this study was to determine the effects of Mg II on
primary cultures of HPT cells that have been previously shown to
maintain many of the characteristics and functions of the PT cell
in vivo and to determine whether such primary cultures of HPT
cells may be used as a model for the human situation in vivo.
In this series of experiments incubation with Ang 11 stimulated
a significant increase in DNA synthesis (day 5) followed by a
significant but later increase in protein synthesis at day 10. The
greatest increase in DNA synthesis was observed following incu-
bation with Mg II (108 M). Mg II (10—10 M) also had a
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Fig. 3. A. The effect of 8-bromo-cAMP on ANG II induced thymidine incorporation into HPT cells following 5, 7 and 10 days exposure to Ang II
(10_sM; N = 4; 'P < 0.01 vs. control; +P < 0.01 vs. iO M Aug II). Symbols are: () control; (tIl) 10_6 8-bromo-cAMP; () i0 M Ang II; ()
108 M Ang II + 10_6 M 8-bromo-cAMP. (B) The effect of 8-bromo-cAMP on total protein content of HPT cells following 7 and 10 days exposure to
Ang II (10 M; N = 4). (C) The effect of 8-bromo-cAMP on Ang II induced uridine incorporation into HPT cells following 7 and 10 days incubation
with Ang II (lO M; N = 4). (D) The effect of 8-bromo-cAMP on Ang IT induced leucine incorporation into HPT cells following 7 and 10 days
incubation with Ang II (10 M) (N 4).
significant but lesser effect, while Ang II (106 M) had no effect on
cell DNA synthesis. Similarly, the greatest increase in protein
synthesis was observed following incubation with Ang II (10_8 M),
although a similar increase was observed following incubation
with Ang 1110 M. Similar concentration dependent effects have
been reported for the actions of Ang II on Na transport in the
rat PT and rat mesangial cell proliferation [6, 27, 28]. Why the
proliferative and hypertrophogenic effects of Ang TI should he
maximal at a concentration of 108 M is difficult to determine.
There are several possible explanations. It has been reported that
the AT1 receptor is rapidly down-regulated or desensitized in the
presence of high saturating levels of Ang II [29]. Sasamura et al
have reported that incubation with low concentrations of Ang II
(1 0 ° M) produced desensitization of the AT1 receptor via a PKC
mediated pathway, while incubation with high doses of Ang II
(l0 M) brought about desensitization via a non-PKC mediated
effect [30]. Recently the AT2 receptor has been reported to
antagonize the proliferative effects of the AT1 receptor, stimula-
tion producing inhibition of cell proliferation [30, 311. Using
radioligand binding we have demonstrated the presence of both
AT1 and AT2 receptors in human proximal tubular cells. Losar-
tan, the ATI -specific ligand blocked 58 4% of Ang II binding
sites, while PD123319, the specific AT2 antagonist, blocked 55
7% of binding sites. Competition studies between [1251]Ang II and
increasing concentrations of Ang IT confirmed the presence of two
site binding for Ang II. Further analysis of data using Radlig
software confirmed a two-site best fit with a high and a low affinity
binding site with Kd values of 0.18 0.07 and 60.6 10.7 and
Bmax values of 0.43 0.10 and 45.7 22.4, respectively. Primary
cultures of HPT cells therefore possess both AT1 and AT2
receptors. It is therefore possible that the growth inhibitory
actions of the AT2 receptor only become apparent at high
"supraphysiological" concentrations of Ang II. Stoll et al have
reported that blockade of the AT2 receptor stimulates prolifera-
tion in a rat vascular smooth muscle cell line, however these
experiments were performed with relatively high concentrations
of Ang II (10- M) [30]. Again, it is possible that the AT2 receptor
is stimulated at higher concentrations of Ang II. Aug II has also
been reported to mediate its effects by two possible pathways, one
mediates a decrease in cAMP via a G protein linked to adenylate
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cyclase, the other stimulates the phosphatidylinositol pathway. It
is possible that low concentrations of Ang II activate the prolif-
erative pathway while high concentrations interact with additional
inhibitory signal transduction pathways. Both AT1 and AT2
receptors are known to be present in PT cells [6, 32], and the AT2
receptor subtype has been reported to be the predominant
subtype in large preglomerular vessels prepared from human
kidney and throughout the tubulointerstitium of normal human
kidney, representing approximately 60% of total Ang II receptors
[33]. The results obtained in this study suggest that both the early
Ang II induction of DNA synthesis and later induction of protein
synthesis are mediated via the AT1 receptor. Both responses were
inhibited in the presence of losartan, the selective AT1 antagonist,
while PD123319, a selective AT2 receptor antagonist, failed to
have any effect. We have previously reported similar results for rat
proximal tubular cells, cultured in serum containing medium [341.
Maximal Ang II stimulation of DNA synthesis was observed at
day 5 of culture when cells were growing rapidly in the form of
small colonies. By day 7 cells had reached confluence and from
this point onwards, Ang II had no effect on [3Hlthymidine uptake
but produced a significant increase in RNA synthesis, de novo
protein synthesis and total protein content, suggesting that Ang II
was stimulating cellular hypertrophy. Wolf et at previously re-
ported that incubation with Ang II (10—s M) stimulated cell
hypertrophy, while inhibiting cell proliferation in an LLC-PK1 cell
line cultured in serum free medium [11]. Unlike Wolf et al our
cells were cultured in serum containing medium and were not
serum rested. Fetal calf serum contains a wide variety of growth
factors [35], and it is now recognized that Ang Il-induced prolif-
eration only occurs in the presence of additional growth factors
including EGF, PDGF and fibroblast growth factor or under
conditions where these factors can be synthesized by the growing
cells [36—381. We have previously reported that FCS is essential
for Ang Il-induced cellular proliferation to occur in primary
cultures of rat proximal tubular cells and it is likely that the same
is true for primary cultures of human proximal tubular cells [341.
It is believed that the AT1 receptor in PT cells is coupled to
adenylate cyclase via a G protein sensitive to pertussis toxin and
that Mg II stimulated hypertrophy is associated with a decrease
in intracellular cAMP concentration [10, 11]. In this series of
experiments incubation of HPT cells with 8-bromo-cAMP
(10_6 NI) completely abolished the cellular response to Ang II,
indicating that the observed Ang Il-induced increase in DNA,
RNA, de novo protein synthesis and total protein content is
mediated by the AT1 receptor and involves down-regulation of
adenylate cyclase probably via a G1 protein.
There is now increasing evidence that PT hypertrophy is an
adaptive response to many physiological and pathological stimuli
and that it is intimately involved in the progression of renal
disease. It is also now clear from both in vivo and in vitro studies
that Ang II is a potent growth factor. The results of this study
clearly demonstrate that Ang II is a potent stimulator of DNA and
protein synthesis in primary cultures of HPT cells, and that both
responses are mediated by the AT1 receptor and fully inhibited by
the AT1 receptor antagonist losartan.
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